Literature DB >> 28624924

Evaluation of hepatic fibrosis: a review from the society of abdominal radiology disease focus panel.

Jeanne M Horowitz1, Sudhakar K Venkatesh2, Richard L Ehman2, Kartik Jhaveri3, Patrick Kamath4, Michael A Ohliger5, Anthony E Samir6, Alvin C Silva7, Bachir Taouli8, Michael S Torbenson9, Michael L Wells2, Benjamin Yeh5, Frank H Miller10.   

Abstract

Hepatic fibrosis is potentially reversible; however early diagnosis is necessary for treatment in order to halt progression to cirrhosis and development of complications including portal hypertension and hepatocellular carcinoma. Morphologic signs of cirrhosis on ultrasound (US), computed tomography (CT), and magnetic resonance imaging (MRI) alone are unreliable and are seen with more advanced disease. Newer imaging techniques to diagnose liver fibrosis are reliable and accurate, and include magnetic resonance elastography and US elastography (one-dimensional transient elastography and point shear wave elastography or acoustic radiation force impulse imaging). Research is ongoing with multiple other techniques for the noninvasive diagnosis of hepatic fibrosis, including MRI with diffusion-weighted imaging, hepatobiliary contrast enhancement, and perfusion; CT using perfusion, fractional extracellular space techniques, and dual-energy, contrast-enhanced US, texture analysis in multiple modalities, quantitative mapping, and direct molecular imaging probes. Efforts to advance the noninvasive imaging assessment of hepatic fibrosis will facilitate earlier diagnosis and improve patient monitoring with the goal of preventing the progression to cirrhosis and its complications.

Entities:  

Keywords:  Chronic liver disease; Elastography; Fibrosis; Magnetic resonance imaging; Perfusion; Sonography

Mesh:

Substances:

Year:  2017        PMID: 28624924      PMCID: PMC5994771          DOI: 10.1007/s00261-017-1211-7

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  187 in total

1.  The diagnosis of cirrhosis by high resolution ultrasound of the liver surface.

Authors:  V Simonovský
Journal:  Br J Radiol       Date:  1999-01       Impact factor: 3.039

2.  Dual-energy (spectral) CT: applications in abdominal imaging.

Authors:  Alvin C Silva; Brian G Morse; Amy K Hara; Robert G Paden; Norio Hongo; William Pavlicek
Journal:  Radiographics       Date:  2011 Jul-Aug       Impact factor: 5.333

3.  MR relaxometry in chronic liver diseases: Comparison of T1 mapping, T2 mapping, and diffusion-weighted imaging for assessing cirrhosis diagnosis and severity.

Authors:  Christophe Cassinotto; Matthieu Feldis; Julien Vergniol; Amaury Mouries; Hubert Cochet; Bruno Lapuyade; Arnaud Hocquelet; Etienne Juanola; Juliette Foucher; François Laurent; Victor De Ledinghen
Journal:  Eur J Radiol       Date:  2015-05-19       Impact factor: 3.528

4.  Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography.

Authors:  Masato Yoneda; Kaori Suzuki; Shingo Kato; Koji Fujita; Yuichi Nozaki; Kunihiro Hosono; Satoru Saito; Atsushi Nakajima
Journal:  Radiology       Date:  2010-06-07       Impact factor: 11.105

5.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

6.  Comparison of T2, T1rho, and diffusion metrics in assessment of liver fibrosis in rats.

Authors:  Hui Zhang; Qihua Yang; Taihui Yu; Xiaodong Chen; Jingwen Huang; Cui Tan; Biling Liang; Hua Guo
Journal:  J Magn Reson Imaging       Date:  2016-08-16       Impact factor: 4.813

7.  T2 relaxation time is related to liver fibrosis severity.

Authors:  Alexander R Guimaraes; Luiz Siqueira; Ritika Uppal; Jamu Alford; Bryan C Fuchs; Suguru Yamada; Kenneth Tanabe; Raymond T Chung; Gregory Lauwers; Michael L Chew; Giles W Boland; Duhyant V Sahani; Mark Vangel; Peter F Hahn; Peter Caravan
Journal:  Quant Imaging Med Surg       Date:  2016-04

Review 8.  Liver fibrosis: from the bench to clinical targets.

Authors:  M Pinzani; K Rombouts
Journal:  Dig Liver Dis       Date:  2004-04       Impact factor: 4.088

9.  Separation of advanced from mild hepatic fibrosis by quantification of the hepatobiliary uptake of Gd-EOB-DTPA.

Authors:  Bengt Norén; Mikael Fredrik Forsgren; Olof Dahlqvist Leinhard; Nils Dahlström; Johan Kihlberg; Thobias Romu; Stergios Kechagias; Sven Almer; Örjan Smedby; Peter Lundberg
Journal:  Eur Radiol       Date:  2012-07-27       Impact factor: 5.315

10.  Utility of Translocator Protein (18 kDa) as a Molecular Imaging Biomarker to Monitor the Progression of Liver Fibrosis.

Authors:  Akiko Hatori; Joji Yui; Lin Xie; Katsushi Kumata; Tomoteru Yamasaki; Masayuki Fujinaga; Hidekatsu Wakizaka; Masanao Ogawa; Nobuki Nengaki; Kazunori Kawamura; Feng Wang; Ming-Rong Zhang
Journal:  Sci Rep       Date:  2015-11-27       Impact factor: 4.379

View more
  27 in total

1.  Feasibility of computed tomography texture analysis of hepatic fibrosis using dual-energy spectral detector computed tomography.

Authors:  ByukGyung Choi; In Young Choi; Sang Hoon Cha; Suk Keu Yeom; Hwan Hoon Chung; Seung Hwa Lee; Jaehyung Cha; Ju-Han Lee
Journal:  Jpn J Radiol       Date:  2020-07-14       Impact factor: 2.374

2.  Liver CT perfusion: which is the relevant delay that reduces radiation dose and maintains diagnostic accuracy?

Authors:  Alessandro Bevilacqua; Silvia Malavasi; Valérie Vilgrain
Journal:  Eur Radiol       Date:  2019-05-21       Impact factor: 5.315

Review 3.  Diagnostic imaging in the management of patients with metabolic syndrome.

Authors:  Seo Rin Kim; Lilach O Lerman
Journal:  Transl Res       Date:  2017-11-22       Impact factor: 7.012

4.  Gd-EOB-DTPA DCE-MRI biomarkers in a rabbit model of liver fibrosis.

Authors:  Yang Ji; Chuanshan Zhang; Zhe Huang; Xia Wang; Lina Yue; Meimei Gao; Huiling Hu; Qinjun Su; Yuedong Han; Bin Liu; Ding Yang; Zhanliang Su; Zhuoli Zhang
Journal:  Am J Transl Res       Date:  2018-09-15       Impact factor: 4.060

5.  Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018.

Authors:  Daniel R Ludwig; Tyler J Fraum; Roberto Cannella; David H Ballard; Richard Tsai; Muhammad Naeem; Maverick LeBlanc; Amber Salter; Allan Tsung; Anup S Shetty; Amir A Borhani; Alessandro Furlan; Kathryn J Fowler
Journal:  Abdom Radiol (NY)       Date:  2019-06

6.  Deep learning for staging liver fibrosis on CT: a pilot study.

Authors:  Koichiro Yasaka; Hiroyuki Akai; Akira Kunimatsu; Osamu Abe; Shigeru Kiryu
Journal:  Eur Radiol       Date:  2018-05-14       Impact factor: 5.315

7.  Dual-source dual-energy CT in the evaluation of hepatic fractional extracellular space in cirrhosis.

Authors:  Antonio Bottari; Salvatore Silipigni; Maria Ludovica Carerj; Antonino Cattafi; Sergio Maimone; Maria Adele Marino; Silvio Mazziotti; Alessia Pitrone; Giovanni Squadrito; Giorgio Ascenti
Journal:  Radiol Med       Date:  2019-10-05       Impact factor: 3.469

8.  Imaging Biomarkers of Hepatic Fibrosis: Reliability and Accuracy of Hepatic Periportal Space Widening and Other Morphologic Features on MRI.

Authors:  Daniel R Ludwig; Tyler J Fraum; David H Ballard; Vamsi R Narra; Anup S Shetty
Journal:  AJR Am J Roentgenol       Date:  2021-03-17       Impact factor: 3.959

9.  Improvement of Gut Diversity and Composition After Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients With or Without Human Immunodeficiency Virus Coinfection.

Authors:  Natthaya Chuaypen; Thananya Jinato; Anchalee Avihingsanon; Sakkarin Chirapongsathorn; Supapon Cheevadhanarak; Intawat Nookaew; Yasuhito Tanaka; Pisit Tangkijvanich
Journal:  J Infect Dis       Date:  2021-10-28       Impact factor: 5.226

10.  Magnetic Resonance Elastography of the Liver: A Single-Institution Review of Cases Performed in a 5-Year Interval.

Authors:  Carlos Morillo-Hernandez; Roberta Catania; Philip J Grosse; Gideon Bollino; Amir A Borhani; Alessandro Furlan
Journal:  J Comput Assist Tomogr       Date:  2022 Jan-Feb 01       Impact factor: 1.826

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.